within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03B_BelladonnaAndDerivativesPlain.A03BB01_Butylscopolamine;

model Butylscopolamine
  extends Pharmacolibrary.Drugs.ATC.A.A03BB01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A03BB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Butylscopolamine, also known as hyoscine butylbromide, is a peripherally-acting antimuscarinic agent commonly used as an antispasmodic for the treatment of abdominal pain and cramps associated with gastrointestinal and genitourinary tract disorders. It does not cross the blood-brain barrier, minimizing central nervous system effects. Butylscopolamine is widely approved and used in many countries today.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Yamamoto, F, et al., &amp; Tamaki, N (2004). Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat. <i>Annals of nuclear medicine</i> 18(7) 637–640. DOI:<a href=\"https://doi.org/10.1007/BF02984589\">10.1007/BF02984589</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15586641/\">https://pubmed.ncbi.nlm.nih.gov/15586641</a></p></li><li><p>Emmott, J, et al., &amp; Wong, WL (2008). The effects of N-butylscopolamine on bowel uptake: an 18F-FDG PET study. <i>Nuclear medicine communications</i> 29(1) 11–16. DOI:<a href=\"https://doi.org/10.1097/MNM.0b013e3282f1d706\">10.1097/MNM.0b013e3282f1d706</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18049092/\">https://pubmed.ncbi.nlm.nih.gov/18049092</a></p></li><li><p>Tytgat, GN (2008). Hyoscine butylbromide - a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. <i>Current medical research and opinion</i> 24(11) 3159–3173. DOI:<a href=\"https://doi.org/10.1185/03007990802472700\">10.1185/03007990802472700</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18851775/\">https://pubmed.ncbi.nlm.nih.gov/18851775</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Butylscopolamine;
